Armodafinil Added to Mood Stabilizers for Depression With Bipolarity
About this title
Study to Evaluate the Efficacy and Safety of Armodafinil Treatment (150 mg/Day) as Adjunctive Therapy in Adults With Major Depression Associated With Bipolar I Disorder
Read the official source — NCT01305408Understand this study
Who was this study for?
This study was for people with depression. Listed age limits: 18 years to 65 years. Other eligibility criteria applied.
- Listed locations
- Birmingham and 129 more locationsSee all locations and recruitment
- Study phase
- Phase 3Usually a larger study designed to confirm effectiveness and safety in a broader group.
Study information
- Recruitment status
- Completed
- Enrollment listed in the registry
- 399
- Sponsor
- Cephalon
- Sponsor type
- Unknown or unclear
- Study type
- Drug
- Intervention type
- Drug
- Study phase
- Phase 3Usually a larger study designed to confirm effectiveness and safety in a broader group.
- Locations
- United States, Argentina, Brazil, ...
- Age range
- From 18 Years to 65 Years
- Official registry ID
- NCT01305408
- Official title
Show the full official title
A Double-Blind, Placebo-Controlled, Parallel-Group, Fixed-Dosage Study to Evaluate the Efficacy and Safety of Armodafinil Treatment (150 mg/Day) as Adjunctive Therapy in Adults With Major Depression Associated With Bipolar I Disorder
Looking for a study you can join?
Explore recruiting studiesRecruitment & locations
Birmingham, United States · Sherman Oaks, United States · Temecula, United States
97 more locations
- Jacksonville Beach, United States
- Lauderhill, United States
- Tampa, United States
- Atlanta, United States
- Park Ridge, United States
- Indianapolis, United States
- Lafayette, United States
- Watertown, United States
- Brooklyn, United States
- New York, United States
- Staten Island, United States
- Wilmington, United States
- Cincinnati, United States
- Toledo, United States
- Oklahoma City, United States
- Allentown, United States
- DeSoto, United States
- Friendswood, United States
- Salt Lake City, United States
- Kirkland, United States
- Spokane, United States
- Buenos Aires, Argentina
- Córdoba, Argentina
- Córdoba Capital, Argentina
- La Plata, Argentina
- La Plata, Buenos Aires, Argentina
- Mendoza, Argentina
- Rosario, Argentina
- Belo Horizonte, Brazil
- Curitiba-Parana, Brazil
- Distrito de Rubiao Junior, Brazil
- Itapira -Sao Paulo, Brazil
- Rio de Janeiro, Brazil
- Salvador, Brazil
- São Paulo, Brazil
- Burgas, Bulgaria
- Kardzhali, Bulgaria
- Kazanlak, Bulgaria
- Pazardzhik, Bulgaria
- Pleven, Bulgaria
- Plovdiv, Bulgaria
- Rousse, Bulgaria
- Sofia, Bulgaria
- Varna, Bulgaria
- Rijeka, Croatia
- Split, Croatia
- Zagreb, Croatia
- Helsinki, Finland
- Kangasala, Finland
- Turku, Finland
- Achim, Germany
- Berlin, Germany
- Cologne, Germany
- Dresden, Germany
- Freiburg im Breisgau, Germany
- Mittweida, Germany
- Budapest, Hungary
- Győr, Hungary
- Nagykálló, Hungary
- Catania, Italy
- Florence, Italy
- Genova, Italy
- Lido Di Camaiore(LU), Italy
- Naples, Italy
- Pisa, Italy
- Roma, Italy
- Bialystok, Poland
- Gdansk, Poland
- Gdynia, Poland
- Krakow, Poland
- Skorzewo, Poland
- Szczecin, Poland
- Tuszyn, Poland
- Belgrade, Serbia
- Kragujevac, Serbia
- Niš, Serbia
- Novi Kneževac, Serbia
- Bojnice, Slovakia
- Bratislava, Slovakia
- Rimavská Sobota, Slovakia
- Rožňava, Slovakia
- Trenčín, Slovakia
- Cape Town, South Africa
- Centurion, South Africa
- Johannesburg, South Africa
- Paarl, South Africa
- Pretoria, South Africa
- Dnipropetrovsk, Ukraine
- Donetsk, Ukraine
- Kharkiv, Ukraine
- Kiev, Ukraine
- Luhansk, Ukraine
- Lviv, Ukraine
- Odesa, Ukraine
- Poltava, Ukraine
- S. Oleksandrivka, Ukraine
- Vinnytsia, Ukraine
Interested in joining this study?
Questions about this study
Who is behind this study?
The study sponsor is Cephalon.
Did this study involve medication?
Yes. The study involved medication, including Armodafinil and Placebo.
Who was this study for?
This study was for people with depression. Listed age limits: 18 years to 65 years. Other eligibility criteria applied.
